The Technical Analyst
Precision BioSciences Inc [DTIL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Precision BioSciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.32% $9.95
America/New_York / 25 apr 2024 @ 12:47
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 68.82 mill |
| EPS: | -332.12 |
| P/E: | -0.0300 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 6.92 mill |
| Avg Daily Volume: | 0.129 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0300 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0300 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.77 - 11.13 ( +/- 11.86%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Smith J. Jefferson | Buy | 31 343 | Restricted Stock Units |
| 2024-04-18 | Amoroso Michael | Buy | 111 217 | Restricted Stock Units |
| 2024-04-18 | Scimeca Dario | Buy | 25 277 | Restricted Stock Units |
| 2024-04-18 | Kelly John Alexander | Buy | 41 705 | Restricted Stock Units |
| 2024-01-20 | Kelly John Alexander | Buy | 116 690 | Common Stock |
| INSIDER POWER |
|---|
| 35.57 |
| Last 99 transactions |
| Buy: 6 131 576 | Sell: 2 082 385 |
Forecast:
14:26 - $9.83
Live Trading Signals (every 1 min)
Forecast
1: 12:56 - $9.98
Forecast 2: 13:46 - $9.74
Forecast 3: 14:26 - $9.83
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.95 (1.32% ) |
| Volume | 0.0123 mill |
| Avg. Vol. | 0.129 mill |
| % of Avg. Vol | 9.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DTIL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Latest Press Releases
2024-04-16 16:15:00 - Press Release
Precision Biosciences Announces Return Of Programs And Conclusion Of Collaboration With Prevail Therapeutics
Durham, n.c.--(business wire)--precision biosciences, inc. (nasdaq: dtil), an advanced gene editing company, today announced the anticipated return of three programs from prevail therapeutics inc., a wholly owned subsidiary of eli lilly and company. precision exercised its option to regain rights for the programs following prevail therapeutics' decision to conclude the collaboration. precision uses its novel proprietary arcus® platform to develop in vivo gene editing therapies for sophisticated.
2024-04-04 11:00:00 - Press Release
Iecure Announces Fda Clearance Of Investigational New Drug Application For Ecur-506 To Initiate Otc-hope Trial For Treatment Of Neonatal Onset Ornithine Transcarbamylase Deficiency In The U.s.
Philadelphia--(business wire)--iecure, inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today clearance of its investigational new drug (ind) application from the u.s. food and drug administration (fda) for ecur-506 in ornithine transcarbamylase (otc) deficiency. ecur-506 will be evaluated in the otc-hope study in newborn males with genet.
2024-03-27 06:45:00 - Press Release
Precision Biosciences Reports Fourth Quarter And Fiscal Year 2023 Financial Results And Provides Business Update
Durham, n.c.--(business wire)--precision biosciences, inc. (nasdaq: dtil), an advanced gene editing company utilizing its novel proprietary arcus® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced financial results for the fourth quarter and fiscal year ended december 31, 2023 and provided a business update. “2023 was a transformative year for precision biosciences as we fully transitioned to our.
2024-03-20 16:30:00 - Press Release
Precision Biosciences To Report Fourth Quarter And Fiscal Year 2023 Results On March 27, 2024
Durham, n.c.--(business wire)--precision biosciences, inc. (nasdaq: dtil), an advanced gene editing company utilizing its novel proprietary arcus® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on march 27, 2024. about precision biosciences, inc. precision biosciences, inc. is an ad.
2024-03-19 07:00:00 - Press Release
Precision Biosciences Presents Preclinical Data Highlighting Pbgene-pmm As A Potential Therapy For Primary Mitochondrial Myopathy
Durham, n.c.--(business wire)--precision biosciences, inc. (nasdaq: dtil), an advanced gene editing company utilizing its novel proprietary arcus® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced a poster presentation highlighting new data for the company's pbgene-pmm program, evaluating an arcus nuclease as a potential treatment for m.3243-associated primary mitochondrial myopathy (pmm). these.
Latest News
2024-04-11 10:55:27 - Zacks Investment Research
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Precision BioSciences, Inc. (DTIL) could be a good stock pick from a technical perspective. DTIL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
2024-04-02 10:56:03 - Zacks Investment Research
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
The consensus price target hints at a 407.9% upside potential for Precision BioSciences (DTIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-04-02 07:51:17 - Zacks Investment Research
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-03-27 09:10:19 - Zacks Investment Research
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $3.35 per share versus the Zacks Consensus Estimate of $3. This compares to loss of $7.81 per share a year ago.
2024-03-20 16:30:00 - Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that it will publish financial results for the fourth quarter and fiscal year 2023 and provide a business update on March 27, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an ad.
2024-02-27 05:26:02 - Zacks Investment Research
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2023-11-30 07:00:00 - Business Wire
Precision BioSciences to Present at Hep-DART 2023
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico. Presentation Details: Title: Precision Biosciences' PBGENE.
2023-10-23 07:00:00 - Business Wire
Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023. Details for the virtual fireside chat are as follows: Date: Wedne.
2023-08-18 11:05:01 - Zacks Investment Research
After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)
The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2023-08-04 09:47:19 - Zacks Investment Research
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.44 per share a year ago.